Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06873035 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Interventional Study of Infigratinib in Children With Hypochondroplasia

Study acronym: HCH
StatusEnrolling by Invitation
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 22 to 24v5
  2. Start date changed from estimate of May 2025 to Apr 22, 2025
    • Secondary endpoints: 7 to 6
    v4
  3. Study sites: 21 to 22v3
  4. Study title shortened, about 1 wordv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib at one of two doses, who have completed at least 26 weeks of participation in QED-sponsored ACCEL (QBGJ398-004).
Trial Details
NCT Number NCT06873035
Lead Sponsor QED Therapeutics, a BridgeBio company
Conditions
(from sponsor)		 Hypochondroplasia
Related terms Bone Diseases, Dwarfism, Genetic Diseases, Inborn, Hypochondroplasia, Mucopolysaccharidosis IV, Musculoskeletal Diseases, Osteochondrodysplasias
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov